Results 61 to 70 of about 12,986,553 (373)
SAGE Open Medicine, 2021 Introduction: Critically ill COVID-19 patients are at increased risk of thrombosis with an enhanced risk of bleeding. We aimed to explore the role of anti-factor Xa levels in optimizing the high-intensity anticoagulation’s safety and efficacy and finding
Mohammed A Hamad +6 more
doaj +1 more source
, 2016 Factor Xa represents an attractive target for antithrombotic drugs as blockade of factor Xa permits inhibition of both the extrinsic and intrinsic coagulation pathways. Several factor Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, have been approved for certain conditions, and are also in clinical development for other indications.
Eduard Shantsila, Gregory YH Lip
openaire +1 more source
Study Of Phenothiazine On p53 Core Domain Mutant Y220C: Finding The Anti-tumor Activity Of Phenothiazine [PDF]
, 2011 The tumor suppressor protein p53 is a transcription factor that plays a key role in the prevention of cancer development. The p53 cancer mutation Y220C induces formation of a cavity on the protein's surface that can accommodate stabilizing small ...
Asif Husain Naqvi +4 more
core +2 more sources
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. [PDF]
, 2014 Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in ...
Amarenco, P +6 more
core +2 more sources
Efficacy and Toxicity of Factor Xa Inhibitors
Journal of Pharmacy & Pharmaceutical Sciences, 2013 Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority.
Maryna Bondarenko +4 more
doaj +1 more source
Intensive Care Medicine Experimental, 2023 Background Optimal anticoagulation strategies for COVID-19 patients with the acute respiratory distress syndrome (ARDS) on venovenous extracorporeal membrane oxygenation (VV ECMO) remain uncertain.
Daniel A. Hofmaenner +16 more
doaj +1 more source
Thrombin and factor Xa link the coagulation system with liver fibrosis
BMC Gastroenterology, 2018 BackgroundThrombin activates hepatic stellate cells via protease-activated receptor-1. The role of Factor Xa (FXa) in hepatic fibrosis has not been elucidated.
A. Dhar +5 more
semanticscholar +1 more source
Biological networks and epistasis in genome-wide association studies [PDF]
, 2007 Over the last few years, technological improvements have made possible the genotyping of hundreds of thousands of SNPs, enabling whole-genome association studies.
Leif Schauser +3 more
core +3 more sources
Factor Xa or thrombin: is factor Xa a better target? [PDF]
Journal of Thrombosis and Haemostasis, 2007 Existing vitamin K antagonists (VKAs) have drawbacks that limit their effectiveness, safety, and overall frequency of use. Oral anticoagulants in development with targeted action against individual coagulation factors, specifically direct factor (F) Xa and IIa inhibitors, appear to have pharmacokinetic and pharmacodynamic properties that overcome the ...
openaire +2 more sources
Cochrane Database of Systematic Reviews, 2018 BACKGROUND Factor Xa inhibitors and vitamin K antagonists (VKAs) are now recommended in treatment guidelines for preventing stroke and systemic embolic events in people with atrial fibrillation (AF).
K. B. Bruins Slot, E. Berge
semanticscholar +1 more source